[{"id":"326fc09f-923f-42f8-96c2-f5c6e69e46e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284385","created_at":"2021-01-18T16:13:32.739Z","updated_at":"2024-07-02T16:35:13.144Z","phase":"Phase 2","brief_title":"Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2","source_id_and_acronym":"NCT03284385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SETD2","pipe":" | ","alterations":" SETD2 mutation","tags":["SETD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SETD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-22"}]